Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. GVK Biosciences Pvt. Ltd.
EIR
•GVK Biosciences Pvt. Ltd.•March 13, 2015

GVK Biosciences Pvt. Ltd. – FDA EIR, Mar 13, 2015

Record Details

An FDA inspection of Clinogent (A Division of GVK Biosciences Pvt. Ltd.) in Ameerpet, India, was conducted from March 10-13, 2015, focusing on a specific bioequivalence study. The inspection revealed several significant issues concerning data integrity and documentation practices. Key violations included the failure to consistently document all electrocardiogram (ECG) files within subject Case Report Forms (CRFs), with multiple ECG recordings for some subjects lacking clear justification for their inclusion or exclusion. Furthermore, there was no documented evidence that subjects were evaluated for adverse events during the wash-out period between study periods, a critical oversight for patient safety monitoring. The facility also failed to maintain complete records for urine drug screening tests, specifically lacking details on the assay system, manufacturer, lot numbers, and expiration dates. Lastly, essential communications between Clinogent and the study sponsor, such as product shipment requests, were not adequately retained in the correspondence files. These observations highlight deficiencies in adhering to regulatory standards for clinical trial conduct and record-keeping. In response, Clinogent committed to providing a formal reply to the FDA's findings within 15 days. Management was also advised to implement rigorous audits of electronic ECG files to ensure comprehensive reporting and appropriate handling. Notably, the firm had already initiated the process of permanently closing its Hyderabad facility, effective June 2015, due to unfavorable business conditions, though regulatory archives were promised to remain accessible.

Company
GVK Biosciences Pvt. Ltd.
Inspection date
March 13, 2015
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Vivek Vardhen Tummala (company_representative)
  • V. Kishan Prasad (company_representative)
  • Amit Kumar Rustagi (company_representative)
  • Naba Kr. Talukdar (other)
  • Nitin S. Lawar (company_representative)
View Company Profile

ID · 38382408-3fb3-4cd1-9e50-c3dcbbfb054d

Violation Codes3
21 CFR 320.38(e)21 CFR 320.38(i)21 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for GVK Biosciences Pvt. Ltd.
  • 483 - 2015-03-13March 13, 2015
  • EIR - 2014-10-09October 9, 2014
  • 483 - 2014-10-09October 9, 2014
  • EIR - 2011-03-30March 30, 2011
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore GVK Biosciences Pvt. Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.